Brickell Biotech is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics for skin diseases. Its pipeline includes BBI-4000 (a topical soft anticholinergic for primary axillary hyperhidrosis), BBI-5000 (a once-daily oral candidate for moderate to severe atopic dermatitis acquired in January 2015), and BBI-2111 (a first-in-class topical anti-inflammatory for mild to moderate atopic dermatitis). Following an IND submission to the FDA in December 2014, the company initiated a randomized, double-blind, vehicle-controlled 180-patient Phase 2b trial of BBI-4000. The company reported positive results from a prior randomized, double-blind, vehicle-controlled pilot study of BBI-4000 and plans additional clinical testing for BBI-5000 later in the year. Brickell intends to use recent financing to support growth and continued development of its pipeline toward regulatory approval and commercialization. The company is based in Miami and emphasizes rapid, cost-effective development and strategic partnerships. Brickell Biotech is a development-stage pharmaceutical company that acquires, develops and aims to commercialize innovative drug therapies for dermatology. Its pipeline includes new chemical entities targeting acne, atopic dermatitis, and hyperhidrosis. The company emphasizes rapid, cost-effective development of product candidates, strategic partnerships, and a diversified portfolio addressing unmet medical needs. Brickell leverages relationships with thought leaders and contract research organizations and is led by a team with prior drug-development exits and dermatology experience. The Series B financing will support advancing novel compounds from pre-clinical proof of concept through clinical testing.

Total raised

$17M

Funding rounds

2

Latest round

Series C

Latest activity

Feb 2015